The Roles of Transmembrane Mucins Located on Chromosome 7q22.1 in Colorectal Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. ACS. 2020.
   Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241. doi:10.3322/caac.2114922700443
   PubMed Web of Science ®Google Scholar
• Keum N, Giovannucci E. Global burden of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–732. doi:10.1038/s41575-019-0189-831455888
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366–378. doi:10.3322/caac.2003819897840
   PubMed Web of Science ®Google Scholar
• Stock C, Pulte D, Haug U, Brenner H. Subsite-specific colorectal cancer risk in the colorectal endoscopy era. Gastrointest Endosc. 2012;75(3):621–630. doi:10.1016/j.gie.2011.10.02522341107
   PubMed Web of Science ®Google Scholar
• Almatroudi A. The incidence rate of colorectal cancer in Saudi Arabia: an observational descriptive epidemiological analysis. Int J Gen Med. 2020;13:977–990. doi:10.2147/IJGM.S27727233149661
   PubMed Web of Science ®Google Scholar
• Zubaidi AM, AlSubaie NM, AlHumaid AA, Shaik SA, AlKhayal KA, AlObeed OA. Public awareness of colorectal cancer in Saudi Arabia: a survey of 1070 participants in Riyadh. Saudi J Gastroenterol. 2015;21(2):78. doi:10.4103/1319-3767.15381925843193
   PubMed Web of Science ®Google Scholar
• Mosli MH, Al-Ahwal MS. Colorectal cancer in the Kingdom of Saudi Arabia: need for screening. APJCP. 2012;13(8):3809–3813. doi:10.7314/apjcp.2012.13.8.380923098475
   PubMed Web of Science ®Google Scholar
• Alsanea N, Abduljabbar AS, Alhomoud S, Ashari LH, Hibbert D, Bazarbashi SJ. Colorectal cancer in Saudi Arabia: incidence, survival, demographics and implications for national policies. Ann Saudi Med. 2015;35(3):196–202. doi:10.5144/0256-4947.2015.19626409793
   PubMed Web of Science ®Google Scholar
• Schmoll H, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–2516. doi:10.1093/annonc/mds23623012255
   PubMed Web of Science ®Google Scholar
• Hammond WA, Swaika A, Mody KJT. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57–84. doi:10.1177/175883401561453026753006
   PubMed Web of Science ®Google Scholar
• Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–117. doi:10.3322/caac.2122024639052
   PubMed Web of Science ®Google Scholar
• Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol. 2011;79(3):224–250. doi:10.1016/j.critrevonc.2010.07.01220719530
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11(2):165–173. doi:10.1016/S1470-2045(09)70335-320005175
   PubMed Web of Science ®Google Scholar
• Brenner H, Bouvier AM, Foschi R, et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer. 2012;131(7):1649–1658. doi:10.1002/ijc.2619221607946
   PubMed Web of Science ®Google Scholar
• Boussios S, Ozturk MA, Moschetta M, et al. The developing story of predictive biomarkers in colorectal cancer. J Pers Med. 2019;9(1):12. doi:10.3390/jpm9010012
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (London, England). 2014;383(9927):1490–1502. doi:10.1016/S0140-6736(13)61649-9
   PubMed Web of Science ®Google Scholar
• Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687–696. doi:10.1056/NEJMoa110037022356322
   PubMed Web of Science ®Google Scholar
• Regueiro CR; Committee AGAFT. AGA future trends committee report: colorectal cancer: a qualitative review of emerging screening and diagnostic technologies. Gastroenterology. 2005;129(3):1083–1103. doi:10.1053/j.gastro.2005.06.01216143145
   PubMed Web of Science ®Google Scholar
• Hurlstone DP, Fujii T. Practical uses of chromoendoscopy and magnification at colonoscopy. Gastrointest Endosc Clin N Am. 2005;15(4):687–702. doi:10.1016/j.giec.2005.08.01416278133
   PubMedGoogle Scholar
• Caderni G, Femia AP, Giannini A, et al. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res. 2003;63(10):2388–2392.12750256
   PubMed Web of Science ®Google Scholar
• Femia AP, Giannini A, Fazi M, et al. Identification of mucin depleted foci in the human colon. Cancer Prev Res (Phila). 2008;1(7):562–567. doi:10.1158/1940-6207.CAPR-08-012519139006
   PubMed Web of Science ®Google Scholar
• Femia AP, Dolara P, Caderni G. Mucin-depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis. Carcinogenesis. 2004;25(2):277–281. doi:10.1093/carcin/bgh00514604897
   PubMed Web of Science ®Google Scholar
• Sierzega M, Młynarski D, Tomaszewska R, Kulig J. Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance. Histopathology. 2016;69(4):582–591. doi:10.1111/his.1299427165582
   PubMed Web of Science ®Google Scholar
• Ho SB, Luu Y, Shekels LL, et al. Activity of recombinant cysteine-rich domain proteins derived from the membrane-bound MUC17/Muc3 family mucins. Biochim Biophys Acta. 2010;1800(7):629–638. doi:10.1016/j.bbagen.2010.03.01020332014
   PubMed Web of Science ®Google Scholar
• Duncan TJ, Watson NFS, Al-Attar AH, Scholefield JH, Durrant LG. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol. 2007;5(1):31. doi:10.1186/1477-7819-5-3117349047
   PubMedGoogle Scholar
• Ho SB, Dvorak LA, Moor RE, et al. Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing. Gastroenterology. 2006;131(5):1501–1517. doi:10.1053/j.gastro.2006.09.00617101324
   PubMed Web of Science ®Google Scholar
• Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Modern Pathol. 2005;18(10):1295–1304. doi:10.1038/modpathol.3800445
   PubMed Web of Science ®Google Scholar
• Wang RQ, Fang DC. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J Clin Pathol. 2003;56(5):378–384. doi:10.1136/jcp.56.5.37812719460
   PubMed Web of Science ®Google Scholar
• Park HU, Kim JW, Kim GE, et al. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas. 2003;26(3):e48–54. doi:10.1097/00006676-200304000-0002212657964
   PubMedGoogle Scholar
• Cao Y, Schlag PM, Karsten U. Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Archiv. 1997;431(3):159–166. doi:10.1007/s0042800500839334836
   PubMed Web of Science ®Google Scholar
• Chang S-K, Dohrman AF, Basbaum CB, et al. Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. Gastroenterology. 1994;107(1):28–36. doi:10.1016/0016-5085(94)90057-48020672
   PubMed Web of Science ®Google Scholar
• Gao S-L, Yin R, Zhang L-F, et al. The oncogenic role of MUC12 in RCC progression depends on c-Jun/TGF-β signalling. J Cell Mol Med. 2020;24(15):8789–8802. doi:10.1111/jcmm.1551532596961
   PubMed Web of Science ®Google Scholar
• Matsuyama T, Ishikawa T, Mogushi K, et al. MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer. Int J Cancer. 2010;127(10):2292–2299. doi:10.1002/ijc.2525620162577
   PubMed Web of Science ®Google Scholar
• Al Amri WS, Allinson LM, Baxter DE, et al. Genomic and expression analyses define MUC17 and PCNX1 as predictors of chemotherapy response in breast cancer. Mol Cancer Ther. 2020;19(3):945–955. doi:10.1158/1535-7163.MCT-19-094031879365
   PubMed Web of Science ®Google Scholar
• Lin S, Zhang Y, Hu Y, et al. Epigenetic downregulation of MUC17 by H. pylori infection facilitates NF-κB-mediated expression of CEACAM1-3S in human gastric cancer. Gastric Cancer. 2019;22(5):941–954. doi:10.1007/s10120-019-00932-030778796
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Yokoyama S, Higashi M, et al. Expression of MUC17 is regulated by HIF1α-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancer. PLoS One. 2012;7(9):e44108–e44108. doi:10.1371/journal.pone.004410822970168
   PubMed Web of Science ®Google Scholar
• Moniaux N, Junker WM, Singh AP, Jones AM, Batra SK. Characterization of human mucin MUC17. Complete coding sequence and organization. J Biol Chem. 2006;281(33):23676–23685. doi:10.1074/jbc.M60030220016737958
   PubMed Web of Science ®Google Scholar
• Gum JR, Crawley SC, Hicks JW, Szymkowski DE, Kim YS. MUC17, a novel membrane-tethered mucin. Biochem Biophys Res Commun. 2002;291(3):466–475. doi:10.1006/bbrc.2002.647511855812
   PubMed Web of Science ®Google Scholar
• Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–2460. doi:10.1056/NEJMra080458820018966
   PubMed Web of Science ®Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–767. doi:10.1016/0092-8674(90)90186-i2188735
   PubMed Web of Science ®Google Scholar
• Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science (New York, N.Y.). 1997;275(5307):1787–1790. doi:10.1126/science.275.5307.1787
   PubMed Web of Science ®Google Scholar
• Silva A-L, Dawson SN, Arends MJ, et al. Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer. 2014;14(1):1–10.24383403
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa150059626028255
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–793. doi:10.1038/ng183416804544
   PubMed Web of Science ®Google Scholar
• Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001;171(1):1–10. doi:10.1016/S0304-3835(01)00528-611485822
   PubMed Web of Science ®Google Scholar
• Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13(12):1270–1275. doi:10.1634/theoncologist.2008-018119056857
   PubMed Web of Science ®Google Scholar
• Tsuchida N, Ohtsubo E, Ryder TJS. Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten murine sarcoma virus. Science (New York, N.Y.). 1982;217(4563):937–939. doi:10.1126/science.6287573
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762. doi:10.1016/S1470-2045(10)70130-320619739
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Frattini M, Arena S, et al. PIK3CA cancer mutations display gender and tissue specificity patterns. Human Mutation. 2008;29(2):284–288. doi:10.1002/humu.2064818022911
   PubMed Web of Science ®Google Scholar
• Nature CGANJ. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330.22810696
   PubMed Web of Science ®Google Scholar
• Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017;30(6):613–621. doi:10.20524/aog.2017.019129118555
   PubMed Web of Science ®Google Scholar
• Schell M, Yang M, Teer J, et al. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun. 2016;7:11743. doi:10.1038/ncomms1174327302369
   PubMed Web of Science ®Google Scholar
• Kaz AM, Wong C-J, Dzieciatkowski S, Luo Y, Schoen RE, Grady WM. Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics. 2014;9(4):492–502. doi:10.4161/epi.2765024413027
   PubMed Web of Science ®Google Scholar
• Xu J-F, Kang Q, Ma X-Y, et al. A novel method to detect early colorectal cancer based on chromosome copy number variation in plasma. Cell Physiol Biochem. 2018;45(4):1444–1454. doi:10.1159/00048757129466793
   PubMedGoogle Scholar
• Herbergs J, Arends JW, Bongers EM, Ramaekers FC, Hopman AH. Clonal origin of trisomy for chromosome 7 in the epithelial compartment of colon neoplasia. Genes Chromosomes Cancer. 1996;16(2):106–112. doi:10.1002/(SICI)1098-2264(199606)16:2<106::AID-GCC4>3.0.CO;2-38818657
   PubMed Web of Science ®Google Scholar
• Uchi R, Takahashi Y, Niida A, et al. Integrated multiregional analysis proposing a new model of colorectal cancer evolution. PLoS Genet. 2016;12(2):e1005778. doi:10.1371/journal.pgen.100577826890883
   PubMed Web of Science ®Google Scholar
• Zarzour P, Boelen L, Luciani F, et al. Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas. Genes Chromosomes Cancer. 2015;54(5):303–314. doi:10.1002/gcc.2224325726927
   PubMed Web of Science ®Google Scholar
• Sato K, Masuda T, Hu Q, et al. Phosphoserine phosphatase is a novel prognostic biomarker on chromosome 7 in colorectal cancer. Anticancer Res. 2017;37(5):2365–2371. doi:10.21873/anticanres.1157428476802
   PubMed Web of Science ®Google Scholar
• Nambara S, Masuda T, Kobayashi Y, et al. GTF2IRD1 on chromosome 7 is a novel oncogene regulating the tumor-suppressor gene TGFβR2 in colorectal cancer. Cancer Sci. 2020;111(2):343–355. doi:10.1111/cas.1424831758608
   PubMed Web of Science ®Google Scholar
• Buishand FO, Cardin E, Hu Y, Ried T. Trichostatin A preferentially reverses the upregulation of gene-expression levels induced by gain of chromosome 7 in colorectal cancer cell lines. Genes Chromosomes Cancer. 2018;57(1):35–41. doi:10.1002/gcc.2250528940826
   PubMed Web of Science ®Google Scholar
• Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta. 2006;1765(2):189–222. doi:10.1016/j.bbcan.2006.01.00216487661
   PubMed Web of Science ®Google Scholar
• Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013;10(10):607–620. doi:10.1038/nrgastro.2013.12023856888
   PubMed Web of Science ®Google Scholar
• Kesari MV, Gaopande VL, Joshi AR, Babanagare SV, Gogate BP, Khadilkar AV. Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature. Indian J Gastroenterol. 2015;34(1):63–67. doi:10.1007/s12664-015-0534-y25731647
   PubMedGoogle Scholar
• Biemer-Huttmann AE, Walsh MD, McGuckin MA, et al. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res. 2000;6(5):1909–1916.10815915
   PubMed Web of Science ®Google Scholar
• Retterspitz MF, Monig SP, Schreckenberg S, et al. Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res. 2010;30(11):4635–4641.21115917
   PubMed Web of Science ®Google Scholar
• Baldus SE, Monig SP, Huxel S, et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res. 2004;10(8):2790–2796. doi:10.1158/1078-0432.CCR-03-016315102686
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun J, Hu X, Huang S. Interference of mucin 1 inhibits progression of colon carcinoma by repression of Wnt/beta-catenin signaling. DNA Cell Biol. 2014;33(3):162–170. doi:10.1089/dna.2013.227424410135
   PubMed Web of Science ®Google Scholar
• Lillehoj EP, Lu W, Kiser T, Goldblum SE, Kim KC. MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism. Biochim Biophys Acta. 2007;1773(7):1028–1038. doi:10.1016/j.bbamcr.2007.04.00917524503
   PubMed Web of Science ®Google Scholar
• Shanmugam C, Jhala NC, Katkoori VR, et al. Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer. 2010;116(15):3577–3586. doi:10.1002/cncr.2509520564074
   PubMed Web of Science ®Google Scholar
• Biemer-Huttmann AE, Walsh MD, McGuckin MA, et al. Immunohistochemical staining patterns of MUC1, MUC2, MUC4, and MUC5AC mucins in hyperplastic polyps, serrated adenomas, and traditional adenomas of the colorectum. J Histochem Cytochem. 1999;47(8):1039–1048. doi:10.1177/00221554990470080810424888
   PubMed Web of Science ®Google Scholar
• Walsh MD, Young JP, Leggett BA, Williams SH, Jass JR, McGuckin MA. The MUC13 cell surface mucin is highly expressed by human colorectal carcinomas. Hum Pathol. 2007;38(6):883–892. doi:10.1016/j.humpath.2006.11.02017360025
   PubMed Web of Science ®Google Scholar
• Gupta BK, Maher DM, Ebeling MC, et al. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. J Histochem Cytochem. 2012;60(11):822–831. doi:10.1369/002215541246067822914648
   PubMed Web of Science ®Google Scholar
• Sheng YH, He Y, Hasnain SZ, et al. MUC13 protects colorectal cancer cells from death by activating the NF-kappaB pathway and is a potential therapeutic target. Oncogene. 2017;36(5):700–713. doi:10.1038/onc.2016.24127399336
   PubMed Web of Science ®Google Scholar
• Huang J, Che M-I, Huang Y-T, et al. Overexpression of MUC15 activates extracellular signal-regulated kinase 1/2 and promotes the oncogenic potential of human colon cancer cells. Carcinogenesis. 2009;30(8):1452–1458. doi:10.1093/carcin/bgp13719520792
   PubMed Web of Science ®Google Scholar
• Duffy M, Bonfrer J, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15(5):679–691. doi:10.1111/j.1525-1438.2005.00130.x16174214
   PubMed Web of Science ®Google Scholar
• Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep. 2018;8(1):2732. doi:10.1038/s41598-018-21048-y29426902
   PubMed Web of Science ®Google Scholar
• Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. J Science. 2002;295(5560):1726–1729.
   PubMed Web of Science ®Google Scholar
• Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131(1):117–129. doi:10.1053/j.gastro.2006.04.02016831596
   PubMed Web of Science ®Google Scholar
• Imai Y, Yamagishi H, Fukuda K, Ono Y, Inoue T, Ueda Y. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma. World J Gastroenterol. 2013;19(25):3957–3968. doi:10.3748/wjg.v19.i25.395723840140
   PubMed Web of Science ®Google Scholar
• Ogata S, Uehara H, Chen A, Itzkowitz SH. Mucin gene expression in colonic tissues and cell lines. Cancer Res. 1992;52(21):5971–5978.1394223
   PubMed Web of Science ®Google Scholar
• Betge J, Schneider NI, Harbaum L, et al. MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. Virchows Arch. 2016;469(3):255–265. doi:10.1007/s00428-016-1970-527298226
   PubMed Web of Science ®Google Scholar
• Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer. 2011;128(8):1860–1871. doi:10.1002/ijc.2577821344374
   PubMed Web of Science ®Google Scholar
• Han Y, Zheng Q, Tian Y, Ji Z, Ye H. Identification of a nine-gene panel as a prognostic indicator for recurrence with muscle-invasive bladder cancer. J Surg Oncol. 2019;119(8):1145–1154. doi:10.1002/jso.2544630887516
   PubMed Web of Science ®Google Scholar
• Maines-Bandiera S, Woo MM, Borugian M, et al. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. Int J Gynecol Cancer. 2010;20(1):16–22. doi:10.1111/IGC.0b013e3181bcc96d20130498
   PubMed Web of Science ®Google Scholar
• Zheng F, Yu H, Lu J. High expression of MUC20 drives tumorigenesis and predicts poor survival in endometrial cancer. J Cell Biochem. 2019.
   Web of Science ®Google Scholar
• Walsh MD, Clendenning M, Williamson E, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Modern Pathol. 2013;26(12):1642–1656. doi:10.1038/modpathol.2013.101
   PubMed Web of Science ®Google Scholar
• Wicking C, Simms LA, Evans T, et al. CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer. Oncogene. 1998;17(5):657–659. doi:10.1038/sj.onc.12019719704932
   PubMed Web of Science ®Google Scholar
• Kawai H, Tomii K, Toyooka S, et al. Promoter methylation downregulates CDX2 expression in colorectal carcinomas. Oncol Rep. 2005;13(3):547–551.15706431
   PubMed Web of Science ®Google Scholar
• Mochizuka A, Uehara T, Nakamura T, Kobayashi Y, Ota H. Hyperplastic polyps and sessile serrated ‘adenomas’ of the colon and rectum display gastric pyloric differentiation. Histochem Cell Biol. 2007;128(5):445–455. doi:10.1007/s00418-007-0326-217851679
   PubMed Web of Science ®Google Scholar
• Vincent A, Perrais M, Desseyn JL, Aubert JP, Pigny P, Van Seuningen I. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene. 2007;26(45):6566–6576. doi:10.1038/sj.onc.121047917471237
   PubMed Web of Science ®Google Scholar
• Renaud F, Vincent A, Mariette C, et al. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer. Int J Cancer. 2015;136(12):2811–2821. doi:10.1002/ijc.2934225403854
   PubMed Web of Science ®Google Scholar
• Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22.32296018
   PubMed Web of Science ®Google Scholar
• Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–885. doi:10.1038/nrc276119935676
   PubMed Web of Science ®Google Scholar
• Chen CH, Wu YJ, Chen JJ. Gold nanotheranostics: photothermal therapy and imaging of Mucin 7 conjugated antibody nanoparticles for urothelial cancer. Biomed Res Int. 2015;2015:813632.25834826
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Nejatollahi F, Ghasemi Y, Faraji SN. Anti-metastatic and anti-invasion effects of a specific anti-MUC18 scFv antibody on breast cancer cells. Appl Biochem Biotechnol. 2017;181(1):379–390. doi:10.1007/s12010-016-2218-127565656
   PubMed Web of Science ®Google Scholar
• Berretta M, Alessandrini L, De Divitiis C, et al. Serum and tissue markers in colorectal cancer: state of art. Crit Rev Oncol Hematol. 2017;111:103–116. doi:10.1016/j.critrevonc.2017.01.00728259285
   PubMed Web of Science ®Google Scholar
• Desseyn JL, Tetaert D, Gouyer V. Architecture of the large membrane-bound mucins. Gene. 2008;410(2):215–222. doi:10.1016/j.gene.2007.12.01418242885
   PubMed Web of Science ®Google Scholar
• Packer LM, Williams SJ, Callaghan S, Gotley DC, McGuckin MA. Expression of the cell surface mucin gene family in adenocarcinomas. Int J Oncol. 2004;25(4):1119–1126.15375564
   PubMed Web of Science ®Google Scholar
• Yang B, Wu A, Hu Y, et al. Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop. J Exp Clin Cancer Res. 2019;38(1):283. doi:10.1186/s13046-019-1279-831262330
   PubMed Web of Science ®Google Scholar
• Krishn SR, Kaur S, Sheinin YM, et al. Mucins and associated O-glycans based immunoprofile for stratification of colorectal polyps: clinical implication for improved colon surveillance. Oncotarget. 2017;8(4):7025–7038. doi:10.18632/oncotarget.1234727705923
   PubMedGoogle Scholar
• Bitler BG, Menzl I, Huerta CL, et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res. 2009;15(1):100–109. doi:10.1158/1078-0432.CCR-08-174519118037
   PubMed Web of Science ®Google Scholar
• Rubinstein DB, Karmely M, Pichinuk E, et al. The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/beta junction mediates cell killing. Int J Cancer. 2009;124(1):46–54. doi:10.1002/ijc.2391018821582
   PubMed Web of Science ®Google Scholar
• Raina D, Ahmad R, Joshi MD, et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009;69(12):5133–5141. doi:10.1158/0008-5472.CAN-09-085419491255
   PubMed Web of Science ®Google Scholar
• Quoix E, Lena H, Losonczy G, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17(2):212–223. doi:10.1016/S1470-2045(15)00483-026727163
   PubMed Web of Science ®Google Scholar
• Wrona A. Role of immunotherapy in stage III nonsmall cell lung cancer. Curr Opin Oncol. 2019;31(1):18–23. doi:10.1097/CCO.000000000000049330489337
   PubMed Web of Science ®Google Scholar
• Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin Biol Ther. 2007;7(11):1723–1730. doi:10.1517/14712598.7.11.172317961094
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME, Redman JM, Donahue RN, et al. A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/brachyury)-based immunotherapy vaccine regimen in patients with advanced cancer. Oncologist. 2020;25(6):479–e899. doi:10.1634/theoncologist.2019-060831594913
   PubMed Web of Science ®Google Scholar
• Chen S, Lin Y, Zhong S, et al. 33O - Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): a pilot study. Ann Oncol. 2018;29:x11. doi:10.1093/annonc/mdy485.002
   PubMed Web of Science ®Google Scholar
• Buckman R, De Angelis C, Shaw P, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol. 1992;47(1):102–109. doi:10.1016/0090-8258(92)90084-V1427388
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Stafford N, Rowlinson-Busza G, Stewart JS, Epenetos AA. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res. 1995;55(5):1060–1069.7866989
   PubMed Web of Science ®Google Scholar
• Nishii Y, Yamaguchi M, Kimura Y, et al. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells. Int J Oncol. 2015;46(4):1781–1787. doi:10.3892/ijo.2015.288025672256
   PubMed Web of Science ®Google Scholar
• Aithal A, Rauth S, Kshirsagar P, et al. MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets. 2018;22(8):675–686. doi:10.1080/14728222.2018.149884529999426
   PubMed Web of Science ®Google Scholar